AesRx, LLC has announced that it plant to enter into a collaboration with the National Institutes of Health (NIH) to take their new sickle cell therapeutic drug, Aes-103, through pre-clinical development and initial clinical trials. Sickle cell anemia is a potentially life threatening disorder that affects red blood cells. People with sickle cell disease have red blood cells that contain mostly hemoglobin* S, an abnormal type of hemoglobin. Sometimes these red blood cells become sickle-shaped (crescent shaped) and have difficulty passing through small blood vessels. Aes-103 is still in its orphan stage, but it apparently targets and reduces blood cell sickling, and it the only drug of its kind to do so. This collaboration will give those afflicted with the disease a chance for a partial cure.
Source [OneMedSentinel]
0 comments:
Post a Comment